Cargando…
Evaluation of population‐level pharmacogenetic actionability in Alabama
The evolution of evidence and availability of Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines have enabled assessment of pharmacogenetic (PGx) actionability and clinical implementation. However, population‐level actionability is not well‐characterized. We leveraged the Alabama G...
Autores principales: | Davis, Brittney H., Williams, Kelly, Absher, Devin, Korf, Bruce, Limdi, Nita A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604228/ https://www.ncbi.nlm.nih.gov/pubmed/34121327 http://dx.doi.org/10.1111/cts.13097 |
Ejemplares similares
-
Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis
por: Anderson, Justin D., et al.
Publicado: (2023) -
338 The Alabama Genomic Health Initiative: Integrating Genomic Medicine into Primary Care
por: Limdi, Nita A, et al.
Publicado: (2023) -
Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012) -
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy
por: Davis, Brittney H., et al.
Publicado: (2021) -
Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples
por: Davis, Brittney H., et al.
Publicado: (2019)